Ameritas Investment Partners, Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

Ameritas Investment Partners, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $22,053 - $46,174	1,088 Added 17.7%	7,236 $306,000
Q3 2023 Nov 13, 2023	BUY	$20.26 - $31.91 $21,029 - $33,122	1,038 Added 20.31%	6,148 $134,000
Q2 2023 Aug 11, 2023	BUY	$23.9 - $35.38 $12,571 - $18,609	526 Added 11.47%	5,110 $162,000
Q4 2022 Feb 13, 2023	BUY	$25.35 - $31.96 $12,877 - $16,235	508 Added 12.46%	4,584 $144,000
Q2 2022 Aug 12, 2022	BUY	$20.62 - $37.15 $20,681 - $37,261	1,003 Added 32.64%	4,076 $107,000
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $6,548 - $11,965	308 Added 11.14%	3,073 $91,000
Q2 2021 Aug 06, 2021	BUY	$12.56 - $29.69 $34,728 - $82,092	2,765 New	2,765 $71,000

270

155M

2.19M

3.92M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.